Wednesday, January 14, 2015 8:06:25 AM
In recent and ongoing work, researchers in the United States have confirmed the potential efficacy of NanoLogix's N-Assay as a rapid indicator for the presence of the current-threat strain of the Ebola virus, EBOV. The research demonstrates a sub-three hour result at present. Researchers are working to refine the test and reduce time-to-detection to facilitate the N-Assay's use as a Point of Care (POC) diagnostic for hemorrhagic and other viruses.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM